Fractures versus placebo
In a randomised, placebo-controlled trial of 1,637 postmenopausal women who already had vertebral fractures, new vertebral fractures occurred in 14% of the placebo group and in 5% and 4% of the two teriparatide groups (relative risks about 0.35 and 0.31) over a median of 21 months. Non-vertebral fragility fractures occurred in 6% of the placebo group and 3% in each teriparatide group. Lumbar spine bone mineral density rose by 9 and 13 percentage points more than with placebo. The authors reported only minor side effects, mainly occasional nausea and headache.
- Study type
- Human trial
- Population
- 1,637 postmenopausal women with prior vertebral fractures; randomised, double-blind, placebo-controlled; subcutaneous injection.
- Source
- 1 Neer et al., 2001
Limitation: Placebo-controlled, so it does not compare teriparatide with other osteoporosis drugs.
Limitations in full
Placebo-controlled, so it does not compare teriparatide with other osteoporosis drugs. Women had prior vertebral fractures, so results may not apply to lower-risk groups. In the higher-strength group, forearm (radial shaft) bone density was lower than with placebo.